Compounded GLP-1s: the cheap era is ending — be careful
Published by GLP-1 Coverage Guide · Updated · No clinician review is credited for this page.
Short answer: Compounded GLP-1 products are not the FDA-approved brand products covered by the Bridge. FDA warns about unapproved GLP-1 products, dosing errors and fraudulent offerings. Ask a licensed clinician and pharmacist about any proposed treatment.
Sources for the coverage rules are listed below. An update date marks a revision; it does not imply a sitewide medical review.
Use the FDA’s current guidance
FDA does not review compounded drugs for safety, effectiveness and quality before marketing. Compounding can have a role when a patient’s medical needs cannot be met by an approved drug, but its legal conditions are specific and can change. This page does not declare all compounding lawful or unlawful.
Keep coverage and product identity separate
CMS’s Bridge list includes Wegovy injections and tablets, Foundayo tablets and Zepbound KwikPen. A compounded semaglutide or tirzepatide offer is not that product list. Confirm the dispensing pharmacy, prescription, product identity and applicable medical guidance.
Take the Medicare eligibility check →
Common questions
Does this calculation establish coverage?
No. It compares the costs you enter; the prescriber and coverage processor determine authorization.
Are all fees included in the $50 Bridge copay?
No. Provider visits, optional memberships and supplies such as Zepbound KwikPen needles can add costs.
Related
Sources: CMS covered formulations and process · CMS prior authorization form · FDA concerns about unapproved GLP-1 products